| 1 |
Computational Insights into the Potential of Withaferin-A, Withanone and Caffeic Acid Phenethyl Ester for Treatment of Aberrant-EGFR Driven Lung Cancers |
|
|
| Vidhi Malik, Vipul Kumar, Sunil C. Kaul, Renu Wadhwa, Durai Sundar |
|
| Biomolecules. 2021; 11(2): 160 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 2 |
MicroRNA-16 Restores Sensitivity to Tyrosine Kinase Inhibitors and Outperforms MEK Inhibitors in KRAS-Mutated Non-Small Cell Lung Cancer |
|
|
| Francesca Fanini, Erika Bandini, Meropi Plousiou, Silvia Carloni, Petra Wise, Paolo Neviani, Mariam Murtadha, Flavia Foca, Francesco Fabbri, Ivan Vannini, Muller Fabbri |
|
| International Journal of Molecular Sciences. 2021; 22(24): 13357 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 3 |
Conformational Insight on WT- and Mutated-EGFR Receptor Activation and Inhibition by Epigallocatechin-3-Gallate: Over a Rational Basis for the Design of Selective Non-Small-Cell Lung Anticancer Agents |
|
|
| Cristina Minnelli, Emiliano Laudadio, Giovanna Mobbili, Roberta Galeazzi |
|
| International Journal of Molecular Sciences. 2020; 21(5): 1721 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 4 |
FGFR1 and FGFR4 oncogenicity depends on n-cadherin and their co-expression may predict FGFR-targeted therapy efficacy |
|
|
| Álvaro Quintanal-Villalonga, Irene Ferrer, Elizabeth Guruceaga, Cristina Cirauqui, Ángela Marrugal, Laura Ojeda, Santiago García, Jon Zugazagoitia, Sandra Muñoz-Galván, Fernando Lopez-Rios, Luis Montuenga, Silvestre Vicent, Sonia Molina-Pinelo, Amancio Carnero, Luis Paz-Ares |
|
| EBioMedicine. 2020; 53: 102683 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 5 |
Tyrosine Kinase Inhibitors in the Treatment of Choroidal Metastases from Non-Small-Cell Lung Cancer: A Case Report and Review of Literature |
|
|
| Akshay Gopinathan Nair, Haresh T. Asnani, Vinod C. Mehta, Siddharth V. Mehta, Rima S. Pathak, Amit H. Palkar, Indumati Gopinathan |
|
| Ocular Oncology and Pathology. 2017; 3(1): 28 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 6 |
24h-gene variation effect of combined bevacizumab/erlotinib in advanced non-squamous non-small cell lung cancer using exon array blood profiling |
|
|
| Florent Baty, Markus Joerger, Martin Früh, Dirk Klingbiel, Francesco Zappa, Martin Brutsche |
|
| Journal of Translational Medicine. 2017; 15(1) |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 7 |
Epidermal Growth Factor Receptor Inhibition in the Management of Squamous Cell Carcinoma of the Lung |
|
|
| Glenwood D. Goss, Johanna N. Spaans |
|
| The Oncologist. 2016; 21(2): 205 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 8 |
Hepatocyte growth factor reduces sensitivity to the epidermal growth factor receptor-tyrosine kinase inhibitor, gefitinib, in lung adenocarcinoma cells harboring wild-type EGFR |
|
|
| Hua Yang, Rong Wang, Shunli Peng, Longhua Chen, Qi Li, Wei Wang |
|
| Oncotarget. 2016; 7(13): 16273 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 9 |
Erlotinib as Second-Line Therapy for Patients with Advanced Non-Small-Cell Lung Cancer and Wild-Type EGFR Tumors |
|
|
| Sergio Vázquez, María José Villanueva, José Luis Fírvida, Begoña Campos, Martín Lázaro, Gerardo Huidobro, María del Carmen Areses, Natalia Fernández, Marta Covela , Joaquín Casal |
|
| Journal of Analytical Oncology. 2015; 4(3) |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 10 |
The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer |
|
|
| Donald L. Smith,Jaime Acquaviva,Manuel Sequeira,John-Paul Jimenez,Chaohua Zhang,Jim Sang,Richard C. Bates,David A. Proia |
|
| Targeted Oncology. 2015; 10(2): 235 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 11 |
S100A4 Is an Independent Prognostic Factor for Patients with Lung Cancer: A Meta-Analysis |
|
|
| Hao Bai,Jia-Lin Qian,Bao-Hui Han |
|
| Genetic Testing and Molecular Biomarkers. 2014; 18(5): 371 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
